| # | Title | Journal | Year | Citations |
|---|
| 1 | Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial | Lancet Oncology, The | 2015 | 2,353 |
| 2 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial | Lancet Oncology, The | 2014 | 823 |
| 3 | Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial | Lancet, The | 2003 | 626 |
| 4 | A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85 | Radiotherapy and Oncology | 1998 | 523 |
| 5 | Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression | Nature Medicine | 2016 | 456 |
| 6 | MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer | JAMA - Journal of the American Medical Association | 2014 | 380 |
| 7 | Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial | BMJ: British Medical Journal | 2009 | 378 |
| 8 | A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: prevalence, severity and impact on quality of life | Supportive Care in Cancer | 2010 | 338 |
| 9 | Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer Patients | Journal of the National Cancer Institute | 1994 | 325 |
| 10 | Functional monitoring of anthracycline cardiotoxicity:a prospective, blinded, long-term observational study of outcome in 120 patients | Annals of Oncology | 2002 | 291 |
| 11 | Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model | British Journal of Cancer | 2005 | 287 |
| 12 | CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use | International Journal of Gynecological Cancer | 2005 | 257 |
| 13 | Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer. | Journal of Clinical Oncology | 1998 | 249 |
| 14 | Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen | Clinical Cancer Research | 2016 | 234 |
| 15 | Surveillance following orchidectomy for stage I seminoma of the testis | European Journal of Cancer | 1993 | 232 |
| 16 | Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial | Lancet, The | 2020 | 226 |
| 17 | A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact | Supportive Care in Cancer | 2010 | 219 |
| 18 | Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic | Annals of Oncology | 1996 | 216 |
| 19 | Salivary gland carcinoma in Denmark 1990–2005: A national study of incidence, site and histology. Results of the Danish Head and Neck Cancer Group (DAHANCA) | Oral Oncology | 2011 | 202 |
| 20 | Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma | Scandinavian Journal of Immunology | 2010 | 200 |
| 21 | Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters | Cancer Immunology, Immunotherapy | 2009 | 181 |
| 22 | The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: Evaluation of the randomised DAHANCA 6&7 trial | Radiotherapy and Oncology | 2011 | 176 |
| 23 | Neurotoxicity secondary to antineoplastic drugs | Cancer Treatment Reviews | 1994 | 163 |
| 24 | Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial | | 2020 | 160 |
| 25 | New Insight Into Epirubicin Cardiac Toxicity: Competing Risks Analysis of 1097 Breast Cancer Patients | Journal of the National Cancer Institute | 2008 | 156 |
| 26 | Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity | Biochimica Et Biophysica Acta - Molecular Basis of Disease | 1997 | 151 |
| 27 | A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma | British Journal of Cancer | 2003 | 151 |
| 28 | Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study. | Journal of Clinical Oncology | 2020 | 150 |
| 29 | The effect of different lung densities on the accuracy of various radiotherapy dose calculation methods: Implications for tumour coverage | Radiotherapy and Oncology | 2009 | 147 |
| 30 | Impact of HPV-associated p16-expression on radiotherapy outcome in advanced oropharynx and non-oropharynx cancer | Radiotherapy and Oncology | 2014 | 144 |
| 31 | A systematic review of dual targeting in HER2-positive breast cancer | Cancer Treatment Reviews | 2014 | 141 |
| 32 | Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. | Biochimica Et Biophysica Acta - Molecular Basis of Disease | 1997 | 139 |
| 33 | Plasma YKL-40: a potential new cancer biomarker? | Future Oncology | 2009 | 137 |
| 34 | P-glycoprotein as multidrug transporter: a critical review of current multidrug resistant cell lines | Biochimica Et Biophysica Acta - Molecular Basis of Disease | 1992 | 136 |
| 35 | Serum YKL-40: A new potential marker of prognosis and location of métastases of patients with recurrent breast cancer | European Journal of Cancer | 1995 | 133 |
| 36 | Importance of overall treatment time for the outcome of radiotherapy of advanced head and neck carcinoma: dependency on tumor differentiation | Radiotherapy and Oncology | 1997 | 133 |
| 37 | MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma | Modern Pathology | 2012 | 133 |
| 38 | High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer | Clinical Cancer Research | 2003 | 123 |
| 39 | Tumor markers in the management of patients with ovarian cancer | Cancer Treatment Reviews | 1995 | 122 |
| 40 | Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma | Cancer | 2006 | 118 |
| 41 | Plasma YKL-40 levels in healthy subjects from the general population | Clinica Chimica Acta | 2011 | 115 |
| 42 | Continuing rise in oropharyngeal cancer in a high HPV prevalence area: A Danish population-based study from 2011 to 2014 | European Journal of Cancer | 2017 | 115 |
| 43 | HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors | Cancer Treatment Reviews | 2009 | 107 |
| 44 | Vaccination with p53-peptide?pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study | Cancer Immunology, Immunotherapy | 2004 | 100 |
| 45 | Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors | Breast | 2013 | 97 |
| 46 | Toremifene and tamoxifen in advanced breast cancer - a double-blind cross-over trial | Breast Cancer Research and Treatment | 1993 | 96 |
| 47 | Evaluation of comorbidity in 9388 head and neck cancer patients: A national cohort study from the DAHANCA database | Radiotherapy and Oncology | 2014 | 94 |
| 48 | Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer. | Journal of Clinical Oncology | 1990 | 93 |
| 49 | Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil | Annals of Oncology | 2008 | 92 |
| 50 | Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy | Lancet, The | 1996 | 88 |
